

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

INSIDE INFORMATION

This announcement is made by Yestar Healthcare Holdings Company Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) made by The Stock Exchange of Hong Kong Limited and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong) (the “**SFO**”).

Reference is made to the announcement of the Company dated 13 November 2017 in relation to the pledging of shares as security of the Loan to Mr. James in favour of the Lender and the announcement of the Company dated 21 January 2025 in relation to the inside information of the appointment of the Receivers (collectively, the “**Announcements**”). Unless otherwise stated herein, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

The Board has been informed by Mr. James that on 7 March 2025 (after trading hours), he has entered into a settlement agreement with the Lender in relation to the Charged Shares in connection with the appointment of the Receivers. As a result, the Receivers over the Charged Shares will retire and the Charged Shares will be released upon full settlement of the agreed amount with reference to the instalment schedule pursuant to the aforementioned settlement agreement.

The Board wishes to emphasise that the abovementioned receivership and entering into the settlement agreement does not concern the Company itself or its assets and the Company’s current business and operation remain as usual.

The Company will update the Shareholders and potential investors of the Company on material developments in relation to the business operation of the Group if and when appropriate in compliance with the Listing Rules and the SFO.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company, and if they are in any doubt about their position, they should consult their professional adviser(s).

By order of the Board
Yestar Healthcare Holdings Company Limited
Liao Changxiang
Executive Director and Chief Executive Officer

Hong Kong, 7 March 2025

As at the date of this announcement, the executive Directors are Ms. Liao Changxiang and Mr. Qiao Jinrong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Mr. Koeswondo Michael David.